

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

**IN RE: OZEMPIC (SEMAGLUTIDE)  
PATENT LITIGATION**

No. 22-md-3038-CFC

**NOVO NORDISK INC. AND NOVO  
NORDISK A/S,**

Plaintiffs/Counterclaim Defendants,

v.

**RIO BIOPHARMACEUTICALS INC., et  
al.,**

C.A. No. 22-294-CFC

Defendants/Counterclaim Plaintiffs.

**NOVO NORDISK INC. and NOVO  
NORDISK A/S,**

No. 22-cv-1040-CFC

Plaintiffs/Counterclaim Defendants,

v.

**MYLAN PHARMACEUTICALS INC.,**

Defendant/Counterclaim Plaintiff.

**OPENING EXPERT REPORT OF WILLIAM J. JUSKO, PH.D.  
REGARDING INVALIDITY OF U.S. PATENT NO. 10,335,462**

# TABLE OF CONTENTS

|                                                                                    | Page |
|------------------------------------------------------------------------------------|------|
| I. QUALIFICATIONS AND BACKGROUND.....                                              | 1    |
| A. EDUCATION AND EXPERIENCE .....                                                  | 1    |
| B. PRIOR TESTIMONY .....                                                           | 5    |
| C. BASIS FOR OPINIONS AND MATERIALS CONSIDERED .....                               | 6    |
| D. RETENTION AND COMPENSATION .....                                                | 6    |
| II. LEGAL STANDARDS .....                                                          | 7    |
| III. PERSON OF ORDINARY SKILL IN THE ART .....                                     | 9    |
| IV. BRIEF SUMMARY OF OPINIONS .....                                                | 11   |
| V. THE '462 PATENT.....                                                            | 12   |
| A. THE SPECIFICATION AND CLAIMS OF THE '462 PATENT.....                            | 12   |
| B. THE PROSECUTION HISTORY OF THE '462 PATENT .....                                | 14   |
| VI. CLAIM CONSTRUCTION .....                                                       | 17   |
| VII. BACKGROUND .....                                                              | 18   |
| A. PHARMACOKINETICS AND PHARMACODYNAMICS.....                                      | 18   |
| B. DRUG DEVELOPMENT – CLINICAL TRIAL DESIGN .....                                  | 21   |
| C. PHARMACOKINETICS AND PHARMACODYNAMICS RELATED TO<br>GLP-1 AND SEMAGLUTIDE ..... | 27   |
| 1. GLP-1 .....                                                                     | 28   |
| 2. GLP-1 derivatives .....                                                         | 29   |
| D. SEMAGLUTIDE CLINICAL TRIALS.....                                                | 36   |
| VIII. SCOPE AND CONTENT OF THE PRIOR ART.....                                      | 41   |
| A. WO '421 .....                                                                   | 42   |
| B. LOVSHIN 2009.....                                                               | 45   |
| C. WO '537 .....                                                                   | 47   |
| D. SEMAGLUTIDE CLINICAL TRIALS.....                                                | 49   |
| 1. NCT00696657.....                                                                | 49   |
| 2. NCT00851773.....                                                                | 51   |

# TABLE OF CONTENTS

(continued)

|                                                                                                                                                                                                        | Page |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| 3. Public Availability of ClinicalTrials.gov.....                                                                                                                                                      | 54   |
| E. KNUDSEN 2004.....                                                                                                                                                                                   | 60   |
| F. LUND.....                                                                                                                                                                                           | 61   |
| G. SEINO .....                                                                                                                                                                                         | 65   |
| H. VICTOZA LABEL .....                                                                                                                                                                                 | 67   |
| I. SHARGEL .....                                                                                                                                                                                       | 69   |
| J. TAMIMI.....                                                                                                                                                                                         | 70   |
| K. FDA EXPOSURE RESPONSE 2003 .....                                                                                                                                                                    | 72   |
| L. ICH 1994 .....                                                                                                                                                                                      | 74   |
| M. KNUDSEN 2010B .....                                                                                                                                                                                 | 77   |
| N. BHANSALI.....                                                                                                                                                                                       | 77   |
| O. MADSBAD 2011.....                                                                                                                                                                                   | 82   |
| P. '833 PATENT .....                                                                                                                                                                                   | 84   |
| Q. ADDITIONAL PRIOR ART AND REFERENCES .....                                                                                                                                                           | 85   |
| IX. INVALIDITY OF THE '462 PATENT .....                                                                                                                                                                | 86   |
| A. CLAIMS 1 AND 3 OF THE '462 PATENT ARE ANTICIPATED BY WO '421, LOVSHIN 2009, OR NCT00696657.....                                                                                                     | 86   |
| 1. WO '421 Anticipated Claims 1 and 3 of the '462 Patent.....                                                                                                                                          | 86   |
| 2. Lovshin 2009 Anticipated Claims 1 and 3 of the '462 Patent.....                                                                                                                                     | 92   |
| 3. NCT00696657 Anticipated Claims 1 and 3 of the '462 Patent.....                                                                                                                                      | 97   |
| B. CLAIMS 1, 3-5, AND 7 OF THE '462 PATENT WOULD HAVE BEEN OBVIOUS .....                                                                                                                               | 101  |
| 1. Claims 1, 3-5, and 7 of the '462 Patent Would Have Been Obvious Over WO '421, NCT00696657, WO '537 and/or Lovshin 2009, Optionally in View of One or More of the '833 Patent and Madsbad 2011 ..... | 101  |

**TABLE OF CONTENTS**  
(continued)

|                                                                                                                          | <b>Page</b> |
|--------------------------------------------------------------------------------------------------------------------------|-------------|
| 2. Claims 1, 3-5, and 7 of the '462 Patent Would Have Been Obvious Over WO '421 Alone or in View of the '833 Patent..... | 120         |
| 3. Claims 1, 3-5, and 7 of the '462 Patent Would Have Been Obvious Over WO '537 in View of Lovshin 2009.....             | 132         |
| X. CONCLUSION.....                                                                                                       | 145         |

## TABLE OF ABBREVIATIONS

| Full Name of Cited Reference                                                                                                                                                                                    | Abbreviation                    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|
| U.S. Patent App. Pub. No. 2011/0166321                                                                                                                                                                          | '321 publication                |
| U.S. Patent No. 10,335,462 (NN-OZEM-000000071-95)                                                                                                                                                               | '462 patent                     |
| Prosecution History for U.S. Patent No. 10,335,462 (NN-OZEM-000003820-4446)                                                                                                                                     | '462 patent prosecution history |
| U.S. Patent App. Pub. No. 2004/0102486                                                                                                                                                                          | '486 publication                |
| U.S. Patent No. 5,512,549                                                                                                                                                                                       | '549 patent                     |
| U.S. Patent No. 8,114,833 (SEMA(JDG)_0000447-68)                                                                                                                                                                | '833 patent                     |
| Bell, <i>Hamster Preproglucagon Contains the Sequence of Glucagon and Two Related Peptides</i> , 302 NATURE 716 (1983)                                                                                          | Bell                            |
| Bhansali, <i>Historical Overview of Incretin Based Therapies</i> , 58 J. ASSOC. OF PHYSICIANS OF INDIA 10 (2010) (SEMA(JDG)_0000014-18)                                                                         | Bhansali                        |
| Blonde, <i>Comparison of Liraglutide Versus Other Incretin-Related Anti-Hyperglycaemic Agents</i> , 14 (suppl. 2) DIABETES, OBESITY & METABOLISM 20 (2012)                                                      | Blonde                          |
| <i>ClinicalTrials.gov Background</i> , CLINICALTRIALS.GOV, <a href="https://clinicaltrials.gov/ct2/about-site/background">https://clinicaltrials.gov/ct2/about-site/background</a> (last visited Mar. 15, 2024) | ClinicalTrials.gov Background   |
| Drab, <i>Incretin-Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects</i> , 30 PHARMACOTHERAPY 609 (2010)                                                                         | Drab                            |
| FDA Guidance for Industry, <i>Exposure-Response Relationships - Study Design, Data, Analysis, and Regulatory Applications</i> (Apr. 2003)                                                                       | FDA Exposure Response 2003      |
| Garber, <i>Efficacy of Metformin in Type II Diabetes: Results of a Double-Blind, Placebo-Controlled, Dose-Response Trial</i> , 102 AM. J. MED. 491 (1997)                                                       | Garber                          |

**TABLE OF ABBREVIATIONS**  
(continued)

| <b>Full Name of Cited Reference</b>                                                                                                                                                                            | <b>Abbreviation</b> |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| <i>Award: ClinicalTrials.gov</i> ,<br><a href="https://ash.harvard.edu/news/clinicaltrials.gov">https://ash.harvard.edu/news/clinicaltrials.gov</a> (last visited Mar. 15, 2024)                               | Harvard Award       |
| Holst, <i>Truncated Glucagon-like Peptide I, an Insulin-Releasing Hormone from the Distal Gut</i> , 211 (2) FEBS LETTERS 169 (1987)                                                                            | Holst               |
| <i>International Conference on Harmonisation; Dose-Response Information to Support Drug Registration; Guideline; Availability</i> , 59 Fed. Reg. 55972 (Nov. 9, 1994)                                          | ICH 1994            |
| EMA, <i>ICH Topic S 7 A Safety Pharmacology Studies for Human Pharmaceuticals</i> (June 2001)                                                                                                                  | ICH 2001            |
| Kirillova, <i>Results and Outcome Reporting in ClinicalTrials.gov, What Makes it Happen?</i> , 7(6) PLoS ONE 1 (2012)                                                                                          | Kirillova           |
| Knudsen, <i>Glucagon-like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes</i> , 47 J. MED. CHEMISTRY 4128 (2004)                                                                          | Knudsen 2004        |
| Knudsen, <i>Liraglutide: The Therapeutic Promise from Animal Models</i> , 64(suppl 167) INT J CLIN PRACT 4 (2010)                                                                                              | Knudsen 2010b       |
| Landersdorfer, <i>Pharmacokinetic/Pharmacodynamic Modelling in Diabetes Mellitus</i> , 47(7) CLIN PHARMACOKINET 417 (2008)                                                                                     | Landersdorfer 2008  |
| Landersdorfer, <i>Mechanism-Based Population Pharmacokinetic Modelling in Diabetes: Vildagliptin as a Tight Binding Inhibitor and Substrate of Dipeptidyl Peptidase IV</i> , 73 Br J Clin Pharmacol 391 (2011) | Landersdorfer 2011a |
| Landersdorfer, <i>Mechanism-Based Population Modelling of the Effects of Vildagliptin on GLP-1, Glucose and Insulin in Patients with Type 2 Diabetes</i> , 73 BR J CLIN PHARMACOL 373 (2011)                   | Landersdorfer 2011b |
| Lovshin, <i>Incretin-Based Therapies for Type 2 Diabetes Mellitus</i> , 5 NATURE REVIEWS ENDOCRINOLOGY 262 (2009) (SEMA(JDG)_0002250-58)                                                                       | Lovshin 2009        |

**TABLE OF ABBREVIATIONS**  
(continued)

| <b>Full Name of Cited Reference</b>                                                                                                                                                                                                                             | <b>Abbreviation</b> |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| Lund, <i>Emerging GLP-1 Receptor Agonists</i> , 16 EXPERT OPINION ON EMERGING DRUGS 607 (2011)                                                                                                                                                                  | Lund                |
| Madsbad, <i>An Overview of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists - Available Efficacy and Safety Data and Perspectives for the Future</i> , 13 DIABETES, OBESITY & METABOLISM 394 (2011) (SEMA(JDG)_0002439-52)                                 | Madsbad 2011        |
| Mojsov, <i>Insulintropin: Glucagon-like Peptide I (7-37) Co-encoded in the Glucagon Gene is a Potent Simulator of Insulin Release in the Perfused Rat Pancreas</i> , 79 J. CLIN. INVEST. 616 (1987)                                                             | Mojsov              |
| Møller, <i>Mechanism-Based Population Modelling for Assessment of L-Cell Function Based on Total GLP-1 Response Following an Oral Glucose Tolerance Test</i> , 38 J. PHARMACOKINET PHARMACODYN 713 (2011)                                                       | Moller              |
| Monami, <i>Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis</i> , 2012 EXPERIMENTAL DIABETES RSCH. 1 (2012)                                                                                                                 | Monami              |
| Murphy, <i>Review of the Safety and Efficacy of Exenatide Once Weekly for the Treatment of Type 2 Diabetes Mellitus</i> , 46 ANN PHARMACOTHER 812 (2012)                                                                                                        | Murphy              |
| Clinical Trial No. NCT00696657 (Internet Archive)                                                                                                                                                                                                               | NCT00696657         |
| Clinical Trial No. NCT00851773 (Internet Archive)                                                                                                                                                                                                               | NCT00851773         |
| Rohatagi, <i>Model-Based Development of a PPAR<math>\gamma</math> Agonist, Rivoglitazone, to Aid Dose Selection and Optimize Clinical Trial Designs</i> , 48 J. CLIN. PHARM. 1420 (2008)                                                                        | Rohatagi            |
| Seino, <i>Dose-Dependent Improvement in Glycemia with Once-Daily Liraglutide without Hypoglycemia or Weight Gain: A Double-Blind, Randomized, Controlled Trial in Japanese Patients with Type 2 Diabetes</i> , 81 DIABETES RSCH. & CLINICAL PRACTICE 161 (2008) | Seino               |
| Shargel, APPLIED BIOPHARMACEUTICS & PHARMACOKINETICS (5th ed. 2005)                                                                                                                                                                                             | Shargel             |

**TABLE OF ABBREVIATIONS**  
(continued)

| <b>Full Name of Cited Reference</b>                                                                                                                                                         | <b>Abbreviation</b> |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| Tamimi, <i>Drug Development: From Concept to Marketing!</i> , 113 NEPHRON CLIN PRACT C125 (2009)                                                                                            | Tamimi              |
| Tasneem, <i>The Database for Aggregate Analysis of ClinicalTrials.gov (AACT) and Subsequent Regrouping by Clinical Specialty</i> , 7(3) PLoS ONE 1(2012)                                    | Tasneem             |
| <i>Victoza</i> , PHYSICIANS' DESK REFERENCE (65th ed. 2010)                                                                                                                                 | Victoza label       |
| International Patent App. Pub. No. WO 2011/058193                                                                                                                                           | WO '193             |
| International Patent App. Pub. No. WO 2011/073328                                                                                                                                           | WO '328             |
| International Patent App. Pub. No. WO 2011/138421 (SEMA(JDG)_0002087-158)                                                                                                                   | WO '421             |
| International Patent App. Pub. No. WO 91/11457                                                                                                                                              | WO '457             |
| International Patent App. Pub. No. WO 2006/097537 (SEMA(JDG)_0002453-528)                                                                                                                   | WO '537             |
| Yun, <i>Pharmacokinetic and Pharmacodynamic Modelling of the Effects of Glimepiride on Insulin Secretion and Glucose Lowering in Healthy Humans</i> , 31 J. CLIN. PHARM. & THER. 469 (2006) | Yun                 |
| Zarin, <i>The ClinicalTrials.gov Results Database—Update and Key Issues</i> , 364 NEW ENGL. J. MED. 852 (2011)                                                                              | Zarin               |

1. My name is William J. Jusko, Ph.D. I have been retained by Mylan Pharmaceuticals Inc., Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc., Rio Biopharmaceuticals Inc. and EMS S/A; Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc.; and Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Limited (collectively, the "defendants"). I understand that Novo Nordisk Inc. and Novo Nordisk A/S (collectively, "Novo Nordisk" or "Plaintiffs") have asserted that the defendants infringe claims 1, 3-5, and 7 of U.S. Patent No. 10,335,462 ("’462 patent"). I have been asked to express my opinions regarding the validity of certain asserted claims of the ’462 patent.

## **I. QUALIFICATIONS AND BACKGROUND**

### **A. EDUCATION AND EXPERIENCE**

2. I am a Professor of Pharmaceutical Sciences at the University of Buffalo School of Pharmacy and Pharmaceutical Sciences. My specialty and research focus broadly include Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, and Pharmacometrics.

3. My research interests also include theoretical, basic, and clinical aspects of the pharmacokinetics and pharmacodynamics of various immunosuppressive agents including corticosteroids, as well as drugs used to treat diabetes, inflammation, and cancer.

362. Moreover, at trial I may rely upon documents and/or other materials produced in this litigation, publicly available documents, and/or any documents the parties have exchanged, such as discovery responses. Additionally, I may rely on visual aids and/or demonstrative exhibits that I prepare or have been prepared on my behalf based upon my opinions.

Dated: 3/19/2024

By:

  
\_\_\_\_\_  
William J. Jusko, Ph.D.